William Blair & Company
KDNY

William Blair & Company’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

William Blair & Company’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,728
Closed -$175K – 2028
2021
Q4 		$175K Sell
10,728
-10,922
-50% -$155K ﹤0.01% 1608
2021
Q3 		$276K Buy
21,650
+10,900
+101% +$143K ﹤0.01% 1366
2021
Q2 		$152K Sell
10,750
-7,000
-39% -$112K ﹤0.01% 1558
2021
Q1 		$276K Buy
+17,750
New +$289K ﹤0.01% 1362
2018
Q4 		– Sell
-16,310
Closed -$599K – 1806
2018
Q3 		$599K Sell
16,310
-1,490
-8% -$47.8K ﹤0.01% 898
2018
Q2 		$623K Sell
17,800
-360
-2% -$13.8K ﹤0.01% 873
2018
Q1 		$844K Sell
18,160
-1,215
-6% -$44.5K 0.01% 755
2017
Q4 		$727K Sell
19,375
-24,831
-56% -$1.08M ﹤0.01% 842
2017
Q3 		$2.35M Buy
44,206
+1,487
+3% +$88.4K 0.02% 522
2017
Q2 		$2.44M Buy
42,719
+4,761
+13% +$239K 0.02% 524
2017
Q1 		$2.13M Buy
37,958
+147
+0.4% +$8.3K 0.02% 528
2016
Q4 		$2.15M Buy
37,811
+284
+0.8% +$17.2K 0.02% 481
2016
Q3 		$2.33M Buy
37,527
+9,321
+33% +$659K 0.02% 460
2016
Q2 		$1.59M Sell
28,206
-1,011
-3% -$61.4K 0.01% 514
2016
Q1 		$1.87M Buy
29,217
+2,829
+11% +$229K 0.02% 470
2015
Q4 		$3.71M Buy
26,388
+8,295
+46% +$1.13M 0.03% 341
2015
Q3 		$1.75M Buy
18,093
+2,335
+15% +$278K 0.02% 569
2015
Q2 		$2.39M Buy
+15,758
New +$2.6M ﹤0.01% 1284

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

William Blair & Company's KDNY Position: Q1 2022 in Review

William Blair & Company sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2022, closing a stake of 10,728 shares — an estimated $175K sold.

William Blair & Company first reported a position in KDNY in Q2 2015 and held it in 18 quarters. The position peaked at $3.71M in Q4 2015. 105 funds tracked by Wall St. Rank hold KDNY as of Q1 2022.

  • William Blair & Company reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 10,728 Chinook Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $175K.
  • William Blair & Company first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
  • William Blair & Company's Chinook Therapeutics, Inc. Common Stock position peaked at $3.71M in Q4 2015.
  • 105 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.